Labisia pumila standardized extract (SKF7®) reduces percentage of waist circumference and waist-to-height ratio in individuals with obesity

IF 5.4 2区医学 Q1 ENDOCRINOLOGY & METABOLISM Diabetes, Obesity & Metabolism Pub Date : 2023-08-08 DOI:10.1111/dom.15229

Yogarabindranath Swarna Nantha PhD, Shalini Vijayasingham MRCP, Noor Lita Adam MMed, Paranthaman Vengadasalam MMed, Mastura Ismail MMed, Norsiah Ali MMed, Li Cheng Chang MMed, Lena Yeap Lay Ling MSc, Thiam-Tsui Tee PhD, Yew-Hoong Cheah PhD

{"title":"Labisia pumila standardized extract (SKF7®) reduces percentage of waist circumference and waist-to-height ratio in individuals with obesity","authors":"Yogarabindranath Swarna Nantha PhD, Shalini Vijayasingham MRCP, Noor Lita Adam MMed, Paranthaman Vengadasalam MMed, Mastura Ismail MMed, Norsiah Ali MMed, Li Cheng Chang MMed, Lena Yeap Lay Ling MSc, Thiam-Tsui Tee PhD, Yew-Hoong Cheah PhD","doi":"10.1111/dom.15229","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>Evidence from the literature points towards a viable choice of utilizing <i>Labisia pumila</i> to improve the metabolic profile in animal studies. To that end, this prospective study was designed to assess the health impact of the consumption of <i>L. pumila</i> standardized extract (SKF7®) on key parameters of obesity in humans such as body weight (BW), body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR).</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>A dose-ranging analysis using SKF7® was conducted through a randomized, double-blind, multicentre, placebo-controlled, phase 2 clinical trial involving individuals with obesity (N = 133) between January 2020 and April 2021. The potential percentage of change was assessed in relation to BW, BMI, WC and WHtR.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Average treatment effect estimates (treatment group vs. placebo) show a statistically significant reduction in the percentage of change for BW (mean = −2.915; CI: −4.546, −1.285), BMI (−2.921; CI: −4.551, −1.291), WC (mean = −2.187; CI: −3.784, −0.589) and WHtR (mean = −2.294, CI: −3.908, −0.681) in the group with a total of 750 mg of SKF7® (<i>p</i> < .01). An incremental reduction in WC and WHtR was consistent with the gradual increase in the total daily concentration of SKF7® from 375 to 750 mg. WC and WHtR had higher effect size (<i>f</i> <sup>2</sup> = 0.11 and <i>f</i> <sup>2</sup> = 0.13 respectively) in comparison with BW and BMI.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.</p>\n </section>\n </div>","PeriodicalId":158,"journal":{"name":"Diabetes, Obesity & Metabolism","volume":"25 11","pages":"3298-3306"},"PeriodicalIF":5.4000,"publicationDate":"2023-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/dom.15229","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes, Obesity & Metabolism","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/dom.15229","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Aim

Evidence from the literature points towards a viable choice of utilizing Labisia pumila to improve the metabolic profile in animal studies. To that end, this prospective study was designed to assess the health impact of the consumption of L. pumila standardized extract (SKF7®) on key parameters of obesity in humans such as body weight (BW), body mass index (BMI), waist circumference (WC) and waist-to-height ratio (WHtR).

Materials and Methods

A dose-ranging analysis using SKF7® was conducted through a randomized, double-blind, multicentre, placebo-controlled, phase 2 clinical trial involving individuals with obesity (N = 133) between January 2020 and April 2021. The potential percentage of change was assessed in relation to BW, BMI, WC and WHtR.

Results

Average treatment effect estimates (treatment group vs. placebo) show a statistically significant reduction in the percentage of change for BW (mean = −2.915; CI: −4.546, −1.285), BMI (−2.921; CI: −4.551, −1.291), WC (mean = −2.187; CI: −3.784, −0.589) and WHtR (mean = −2.294, CI: −3.908, −0.681) in the group with a total of 750 mg of SKF7® (p < .01). An incremental reduction in WC and WHtR was consistent with the gradual increase in the total daily concentration of SKF7® from 375 to 750 mg. WC and WHtR had higher effect size (f ² = 0.11 and f ² = 0.13 respectively) in comparison with BW and BMI.

Conclusions

SKF7® is potentially a novel therapeutic treatment for obesity, reflected by reductions in BW, BMI, WC and WHtR. The use of SKF7® suggests a dose-dependent reduction in abdominal obesity, exemplified by a decline in WC and WHtR.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Labisia pumila标准提取物（SKF7®）可降低肥胖患者的腰围百分比和腰高比

目的从文献中获得的证据表明，在动物研究中，利用浮沙来改善代谢状况是一种可行的选择。为此，这项前瞻性研究旨在评估食用浮萍标准化提取物（SKF7®）对人类肥胖关键参数的健康影响，如体重（BW）、体重指数（BMI）、腰围（WC）和腰高比（WHtR）。材料和方法通过一项随机、双盲、多中心、安慰剂对照的2期临床试验，使用SKF7®进行剂量范围分析，该试验涉及肥胖个体（N = 133）。评估了与体重、BMI、WC和WHtR相关的潜在变化百分比。结果平均治疗效果估计值（治疗组与安慰剂组）显示BW的变化百分比（平均 = −2.915；CI:−4.546，−1.285）、BMI（−2.921；CI:−4.5 51，−1.291）、WC（平均值 = −2.187；CI:−3.784，−0.589）和WHtR（平均值 = −2.294，CI:−3.908，−0.681），共750 mg SKF7®（p <； .01）。WC和WHtR的逐渐减少与SKF7®的日总浓度从375逐渐增加到750一致 mg。WC和WHtR具有更高的效应大小（f 2. = 0.11和f 2. = 0.13）。结论SKF7®是一种潜在的新型肥胖治疗方法，可降低体重、BMI、WC和WHtR。SKF7®的使用表明，腹部肥胖的减少呈剂量依赖性，WC和WHtR的下降就是例证。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Diabetes, Obesity & Metabolism 医学-内分泌学与代谢

CiteScore

10.90

自引率

6.90%

发文量

319

审稿时长

3-8 weeks

期刊介绍： Diabetes, Obesity and Metabolism is primarily a journal of clinical and experimental pharmacology and therapeutics covering the interrelated areas of diabetes, obesity and metabolism. The journal prioritises high-quality original research that reports on the effects of new or existing therapies, including dietary, exercise and lifestyle (non-pharmacological) interventions, in any aspect of metabolic and endocrine disease, either in humans or animal and cellular systems. ‘Metabolism’ may relate to lipids, bone and drug metabolism, or broader aspects of endocrine dysfunction. Preclinical pharmacology, pharmacokinetic studies, meta-analyses and those addressing drug safety and tolerability are also highly suitable for publication in this journal. Original research may be published as a main paper or as a research letter.